The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Update on cannabinoids to treat pain

    Here are highlights from the American Academy of Pain Medicine 23rd Annual Meeting

    Sativex Oromucosal Spray

    Contains delta-9-tetrahydrocannabinol and cannabidiol

    • Well tolerated in clinical studies
    • Cannabidiol reduces the psychoactive effects of tetrahydrocannabinol
    • Intoxication is less than with oral tetrahydrocannabinol

    Sativex clinical studies in patients with multiple sclerosis

    • 160 outpatients with multiple sclerosis had a significant reduction of spasticity compared to placebo
    • Analysis of studies of 666 patients, showed that Sativex was significantly superior to placebo.

    Sativex is approved in Canada to treat neuropathic pain generated in patients with multiple sclerosis. The US Food and Drug Administration has approved phase 3 studies to evaluate it in patients with cancer.

    3/31/07 23:06 JR

    Leave a Comment

    You must be logged in to post a comment.